Stevens-Johnson Syndrome: Causes, Symptoms & Treatment

Stevens-Johnson Syndrome: Understanding This Rare Skin Disorder

Stevens-Johnson syndrome (SJS) is a rare but serious disorder affecting the skin and mucous membranes throughout the body. It typically develops as a severe reaction to medication, beginning with flu-like symptoms and progressing to a painful rash that blisters and spreads. The condition represents a medical emergency that requires immediate hospitalization and specialized care. Understanding its causes, symptoms, and treatment options is critical for patients, families, and healthcare providers.

A more severe variant of this condition exists, called toxic epidermal necrolysis (TEN), which involves extensive damage to more than 30% of the body’s skin surface. Together, SJS and TEN form a spectrum of severe cutaneous adverse reactions (SCAR) that demand urgent medical intervention.

What Is Stevens-Johnson Syndrome?

Stevens-Johnson syndrome is classified as a severe cutaneous adverse drug reaction (SCAR) that is immunologically mediated and potentially life-threatening. The condition was first described in medical literature in 1922 by doctors A.M. Stevens and F.C. Johnson, giving it its distinctive name. A related severe variant, toxic epidermal necrolysis, was identified later in 1956 by Dr. A. Lyell and is sometimes referred to as Lyell syndrome.

The syndrome represents a spectrum of disease differentiated primarily by the percentage of body surface area (BSA) involved. SJS affects less than 10% of the body surface area, while the SJS/TEN overlap syndrome involves 10% to 30% of the BSA. When more than 30% of the body surface area is affected, the condition is classified as toxic epidermal necrolysis.

Causes and Risk Factors

Medication Triggers

Medications are the dominant trigger of Stevens-Johnson syndrome and toxic epidermal necrolysis. While various drugs can precipitate this reaction, certain medication classes carry higher risk. Common culprits include penicillin antibiotics, sulfa-based antibiotics, anticonvulsant medications, and cyclooxygenase-2 (COX-2) inhibitors. Patients who develop SJS must permanently avoid the triggering drug and chemically related medications to prevent recurrence.

Genetic Predisposition

Beyond medication exposure, genetic factors play a crucial role in determining who develops this severe reaction. There is a well-documented genetic predisposition in certain ethnic groups and individuals carrying specific human leukocyte antigen (HLA) variants. HLA proteins are found on most cells in the body and help the immune system distinguish between cells that belong and those that are foreign. For example, individuals of Chinese or Southeast Asian ancestry who carry the HLA B*1502 gene variant face significantly increased risk when taking carbamazepine, an anti-seizure medication.

Required Conditions for Development

Interestingly, medication exposure alone is typically insufficient to trigger SJS/TEN. Additional predisposing factors must be present simultaneously. The combination of genetic susceptibility, specific medication exposure, and possibly other environmental or immunological factors converges to create the perfect storm for this rare but severe reaction.

Signs and Symptoms

Initial Presentation

Most cases of Stevens-Johnson syndrome begin with general, non-specific symptoms that resemble the flu. Patients typically experience fever, body aches, malaise, and general discomfort. These early symptoms usually precede visible skin involvement by several days and characteristically develop one to eight weeks after exposure to the triggering medication.

Early Symptoms Include:

– Burning or stinging sensation in the eyes
– Difficulty swallowing or throat discomfort
– Headaches and chills
– Joint pain and body aches
– Purulent cough with mucous and sputum
– General feeling of poor health and fatigue

Progression to Skin Involvement

After the initial flu-like phase, characteristic skin changes develop. Red, flat spots (erythematous macules) appear and may quickly spread to cover large portions of the body. These lesions progress to painful blistering of the skin and mucous membranes. The blistering can involve the eyes, lips, mouth, nose, and genital areas. In severe cases, internal organs may become involved, potentially leading to multi-organ failure.

Complications

Skin and Wound Complications

The extensive skin damage characteristic of SJS/TEN creates multiple serious complications. Where the skin has shed, the body loses significant fluid, predisposing patients to severe dehydration. Additionally, the widespread open wounds expose patients to infection risk, including the potentially fatal complication of sepsis—a life-threatening condition where bacteria spread through the bloodstream causing systemic inflammation and organ dysfunction.

Ocular Complications

Eye involvement represents one of the most challenging long-term complications. The inflammatory process can cause significant damage to eye tissue, resulting in scarring, vision loss, and in rare cases, complete blindness. The disease can cause symblepheron (adhesion between eyelid and eyeball) and destruction of limbal stem cells, leading to chronic corneal abrasions. These complications often persist long after the acute phase resolves.

Respiratory and Digestive Tract Involvement

The mucous membranes lining the respiratory and digestive tracts are particularly vulnerable. Involvement of these tissues can lead to lung damage, bronchitis, chronic obstructive pulmonary disease, and esophageal scarring. Additionally, patients may develop dental complications including xerostomia (dry mouth), inflammation of the gums, and gum disease due to changes in saliva production and quality.

Mortality and Severe Outcomes

The mortality rate for Stevens-Johnson syndrome ranges from 1% to 5%, while toxic epidermal necrolysis carries a much higher mortality rate of approximately 30%. Patients with TEN may resemble individuals with severe thermal burns in physical appearance, metabolic abnormalities, and critical care requirements. Individuals with extensive body surface area involvement often require intensive care unit management with specialized wound care, fluid management, and infection prevention protocols.

Diagnosis

Stevens-Johnson syndrome is primarily a clinical diagnosis based on characteristic presentation and history. Healthcare providers typically consider the timeline of medication exposure, the pattern of skin involvement, and the presence of mucous membrane involvement. Skin biopsy may be performed to confirm the diagnosis and rule out other conditions. Laboratory tests may be ordered to assess organ function and detect complications such as infection or electrolyte imbalances.

Treatment Approaches

Immediate Management

The cornerstone of management in the acute phase is comprehensive supportive care. The first critical step is immediate cessation of the suspected culprit medication and any other non-essential drugs. This action alone can halt disease progression and prevent further deterioration. Patients require hospitalization for intensive monitoring and management of this medical emergency.

Supportive Care

Supportive care encompasses multiple essential interventions. Wound care is critical, involving careful management of blistered areas to prevent infection and promote healing. Patients require careful fluid and electrolyte management to prevent dehydration and maintain organ function. Pain control is essential and may require potent analgesics. Eye care is particularly important and may involve ophthalmologic consultation to prevent or minimize vision loss.

Systemic Therapies

While no standard guidelines exist for systemic drug therapy, several treatment approaches have shown benefit. These include cyclosporine, which suppresses immune function; systemic corticosteroids such as dexamethasone or methylprednisolone, often administered in pulsed high-dose regimens; intravenous immunoglobulins, particularly beneficial in children during early disease stages; and tumor necrosis factor antagonists (anti-TNF agents) such as etanercept and infliximab. The choice of systemic therapy depends on disease severity, patient factors, and institutional protocols.

Long-Term Management

Recovery from Stevens-Johnson syndrome can take weeks to months. Long-term complications require ongoing specialist care. Ophthalmologic follow-up is essential for patients with eye involvement. In some cases of severe corneal scarring with absent tear function, advanced interventions such as keratoprosthesis (KPro) may be considered as a last resort to restore functional vision. Emerging research is exploring combinations of stem cell grafting with keratoprosthesis to create a more favorable ocular surface.

Prevention

Medication Avoidance

Patients who have experienced Stevens-Johnson syndrome must permanently avoid the triggering medication and closely related drugs. Healthcare providers should be clearly informed of the SJS history to prevent accidental re-exposure. Patients benefit from maintaining a detailed medication allergy list and discussing their history with all healthcare providers.

Genetic Screening

For individuals of Chinese or Southeast Asian ancestry, genetic testing for HLA B*1502 is recommended before prescribing carbamazepine and related anticonvulsants. This screening can identify high-risk individuals and guide medication selection, potentially preventing serious reactions.

Recovery and Long-Term Outlook

For patients who survive the acute phase, recovery depends on disease severity and extent of complications. Many pediatric patients return to normal function except for persistent eye problems. The skin typically regenerates over weeks to months, though scarring may occur in areas of severe damage. Eye complications remain the most challenging long-term consequence, with many patients experiencing chronic dryness, scarring, and reduced vision. Psychological support may be beneficial as patients cope with the trauma of this severe illness and potential long-term disability.

Frequently Asked Questions

Q: How quickly does Stevens-Johnson syndrome develop after medication exposure?

A: Symptoms typically appear one to eight weeks after exposure to the triggering medication. Initial flu-like symptoms precede skin involvement by several days.

Q: Is Stevens-Johnson syndrome contagious?

A: No, Stevens-Johnson syndrome is not contagious. It is an individual immunologic reaction to medication and cannot be transmitted to other people.

Q: Can Stevens-Johnson syndrome occur with over-the-counter medications?

A: Yes, SJS can be triggered by both prescription and over-the-counter medications, including common pain relievers and antibiotics.

Q: What is the difference between Stevens-Johnson syndrome and toxic epidermal necrolysis?

A: The primary difference is the percentage of body surface area affected. SJS involves less than 10%, while TEN involves more than 30%. SJS/TEN overlap occurs when 10-30% is involved. TEN generally carries higher mortality risk.

Q: Are there any warning signs that someone might develop SJS?

A: Early warning signs include unexpected fever, sore throat, burning eyes, and body aches occurring days to weeks after starting a new medication, especially antibiotics or anticonvulsants.

Q: Can Stevens-Johnson syndrome recur?

A: Recurrence is possible if the triggering medication is re-exposed. This is why permanent avoidance of the causative drug and related medications is essential.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete